Can Dyne Therapeutics, Inc. cover its short-term obligations?

Its current ratio is 19.92 — current assets exceed current liabilities.

Where does Dyne Therapeutics, Inc.'s balance sheet data come from?

Every line is extracted from Dyne Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Dyne Therapeutics, Inc. DYN Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$893.37M+105%	$435.45M+258%	$121.63M-29.3%	$172.15M-14.3%
Short-term investments	$217.19M+5.0%	$206.82M+13,931%	$1.47M-98.2%	$83.87M-52.3%
Prepaid expenses and other current assets	$56.44M-27.5%	$77.8M+135%	$33.11M-29.7%	$47.07M-10.6%
Total current assets	$1.13B+70.9%	$659.28M+410%	$129.38M-51.3%	$265.59M-30.5%
Property and equipment, net	$24.03M+345%	$5.4M+12.9%	$4.78M-19.6%	$5.95M+27.1%
Operating lease right-of-use assets	$20.74M-15.7%	$24.62M-14.0%	$28.61M-11.9%	$32.47M-10.5%
Total assets	$1.19B+71.7%	$691.23M+319%	$165.08M-46.1%	$306.33M-28.0%
Accounts payable	$8.08M+23.2%	$6.56M-71.4%	$22.94M+336%	$5.26M+30.5%
Accrued expenses	$37.55M+21.7%	$30.85M+31.6%	$23.44M+28.7%	$18.22M-12.4%
Operating lease liabilities, current	$5M+3.0%	$4.85M+2.8%	$4.72M+2.4%	$4.61M+18.4%
Total current liabilities	$50.63M+19.8%	$42.26M-17.3%	$51.1M+81.9%	$28.09M-2.2%
Long-term debt	$148.92M—	$0—	——	——
Operating lease liabilities, non-current	$15.28M-20.1%	$19.14M-15.7%	$22.7M-12.3%	$25.87M-10.0%
Total liabilities	$214.83M+250%	$61.4M-16.8%	$73.79M+36.7%	$53.96M-6.1%
Preferred stock	$0—	$0—	$0—	$0—
Common stock	$16K+60.0%	$10K+66.7%	$6K0.0%	$6K0.0%
Additional paid-in capital	$2.37B+49.9%	$1.58B+118%	$723.8M+11.4%	$649.5M+8.8%
Retained earnings	-$1.4B-47.0%	-$949.93M-50.2%	-$632.51M-59.5%	-$396.57M-73.6%
Accumulated other comprehensive income (loss)	$475K+7,817%	$6K—	$0+100%	-$571K-112%
Total stockholders' equity	$972.13M+54.3%	$629.84M+590%	$91.29M-63.8%	$252.36M-31.5%
Total liabilities and stockholders' equity	$1.19B+71.7%	$691.23M+319%	$165.08M-46.1%	$306.33M-28.0%
Available For Sale Securities Debt Securities Current	$217.19M+5.0%	$206.82M+13,931%	$1.47M-98.2%	$83.87M-52.3%
Net Investment in Lease	$20.74M-15.7%	$24.62M-14.0%	$28.61M-11.9%	$32.47M-10.5%
Operating lease right-of-use assets	$20.74M-15.7%	$24.62M-14.0%	$28.61M-11.9%	$32.47M-10.5%
Restricted Cash And Other Assets Noncurrent	$15.6M+703%	$1.94M-16.1%	$2.32M-0.2%	$2.32M+0.3%
Operating Lease Right-of-Use Assets in Other Assets	$20.74M-15.7%	$24.62M-14.0%	$28.61M-11.9%	$32.47M-10.5%
Vendor Financing Arrangement	——	——	——	——
Accrued expenses and other liabilities	$37.55M+21.7%	$30.85M+31.6%	$23.44M+28.7%	$18.22M-12.4%
Total debt	$169.2M+605%	$23.99M-12.5%	$27.42M-10.1%	$30.48M-6.6%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$16K+60.0%	$10K+66.7%	$6K0.0%	$6K0.0%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Dyne Therapeutics, Inc. cover its short-term obligations?: Its current ratio is 19.92 — current assets exceed current liabilities.
Where does Dyne Therapeutics, Inc.'s balance sheet data come from?: Every line is extracted from Dyne Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.